15:08

6504750359 → USPTO CENTRAL

OCT 2 0 2005

NO.106 D001

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0851-0051
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/719,102 Filing Date TRANSMITTAL November 21, 2003 First Named Inventor **FORM** Elfatih Elzein Art Unit 1624 Examiner Name BERCH, Mark L. (to be used for all correspondence after initial filing) Attorney Docket Number 01-0163-CIP2 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer below). Extension of Time Request Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Remarks Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Therapeutics, In-Signature Printed name J. Elin Hartrum Reg. No. Date 43,663 Øctober 20, 2005

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail from chivelege addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

(571) 273-8300

Signature

Jusan Chican

Typed or printed name

Susan Ahearn

Date 10/20/2005

This collection of information is required by 37 CFR 1.5. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any comments on the amount of time you require to complete this form end/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED CENTRAL FAX CENTER

OCT 2 0 2005

Atty Dkt No. 01-0163-CIP2 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Elzein et al

Confirmation No.: 1946

Serial No.: 10/719,102

15:08

Group Art Unit: 1624

Filing Date: November 21, 2003

Examiner: BERCH, Mark L.

Title: A2B ADENOSINE RECEPTOR ANTAGONISTS

STATUS INQUIRY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

On November 21, 2003, the referenced application was filed with the United States

Patent and Trademark Office. The case was docketed as ready for examination on June 8, 2004.

No communication has been received from the Patent and Trademark Office to date. Applicants respectfully request to be informed of the current status of this application.

Respectfully submitted,

By:

J. Elin Hartrum

Registration No. 43,663 Customer No. 27716

CV THERAPEUTICS, INC. 3172 Porter Drive Palo Alto, CA 94304 (650) 384-8755 Telephone (650) 475-0359 Facsimile